Stocks Health care VIR
NASDAQ · Health careVir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. brought in $302.8M of revenue over the twelve months to September 30, 2026, up 1,696.0% from a year earlier. It posted a net loss of $184.8M. In fiscal 2025 capital spending exceeded operating cash flow by $396.6M. At September 30, 2026 it held $218.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Vir Biotechnology, Inc.
- Net worth
- Vir Biotechnology, Inc. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of $896M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $68.6M (-7.6% year on year), with a net loss of $438M. Over the 12 months to September 30, 2026: revenue $302.8M, net loss $184.8M.
- Cash flow
- In fiscal 2025 operations used $391.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vir Biotechnology, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Vir Biotechnology, Inc. does
Vir Biotechnology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VIR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $68.6M | -$438M | -$3.16 | -$396.6M |
| 2024 | $74.2M | -$522M | -$3.83 | -$453.7M |
| 2023 | $86.2M | -$615.1M | -$4.59 | -$800.4M |
| 2022 | $1.6B | $515.8M | $3.83 | $1.6B |
| 2021 | $1.1B | $528.6M | $3.96 | -$69.4M |
| 2020 | $76.4M | -$298.7M | -$2.51 | -$197.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VIR ranks in Health care
Latest SEC filings
What Vir Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 6, 2026Activist stake changed SCHEDULE 13D/A
- November 4, 2026
- November 4, 2026
- October 28, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 14, 2026
- October 8, 2026Other event 8-K
- October 1, 2026Executive or director change8-KVir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 19,583% to $238.9M versus the same quarter last year; diluted EPS $0.47 versus -$0.80.
Insider trades
What the people running Vir Biotechnology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $41.9K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | de Verneuil VaninaEVP, General Counsel, Corp Sec | Soldpre-planned (10b5-1) | 2,407 | $26.7K |
| November 2, 2026 | de Verneuil VaninaEVP, General Counsel, Corp Sec | Soldpre-planned (10b5-1) | 1,343 | $15.2K |
| October 27, 2026 | Topalian Suzanne LouiseDirector | Received as pay | 8,000 | - |
| October 27, 2026 | Topalian Suzanne LouiseDirector | Received as pay | 4,731 | - |
| August 11, 2026 | More Robert JDirector | Other change | 8,000 | - |
| August 11, 2026 | More Robert JDirector | Other changeindirect | 8,000 | - |
| June 9, 2026 | Coughlin TimothyDirector | Received as pay | 8,000 | - |
| June 9, 2026 | Coughlin TimothyDirector | Received as pay | 8,000 | - |
Who owns VIR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 12.4% | October 27, 2026 |
| Robert Nelsen13D, may seek influence with 7 related filers | 7.3% | November 6, 2026 |
| Vanguard Portfolio Management13G, passive | 6.85% | July 31, 2026 |
| SB Investment Advisers (UK) Limited13G, passive with 2 related filers | 6.5% | May 15, 2026 |
Largest institutional holders
Insiders
15 insiders reported holding 17,038,777 shares in total, about $232.5M at the last price.
| Holder | Shares |
|---|---|
| SVF Endurance (Cayman) Ltd10% owner | 13,728,92413,728,924 held indirectly |
| Sato Vicki LDirector | 1,078,391 |
| De Backer MariannePresident and CEO, Director | 1,001,263286,650 held indirectly |
| More Robert JDirector | 558,573517,917 held indirectly |
| O'Byrne JasonEVP & Chief Financial Officer | 162,6152,500 held indirectly |
| Eisner MarkEVP and Chief Medical Officer | 154,024 |
| de Verneuil VaninaEVP, General Counsel, Corp Sec | 110,193 |
| Sabatini BrentSVP, Chief Accounting Officer | 61,902 |
| Sigal Charles ElliottDirector | 39,806 |
| Hatfield Jeffrey S.Director | 39,806 |
Questions about VIR
What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc. is a company in the Health care sector, listed on NASDAQ as VIR. Its shares trade on NASDAQ under the ticker VIR.
What is Vir Biotechnology, Inc.'s net worth?
Vir Biotechnology, Inc. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of $896M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vir Biotechnology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $184.8M on revenue of $302.8M.
How much revenue does Vir Biotechnology, Inc. make?
Over the twelve months to September 30, 2026 Vir Biotechnology, Inc. reported revenue of $302.8M. That is 1,696.0% more than a year earlier.
When did Vir Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Vir Biotechnology, Inc.'s next earnings report?
Vir Biotechnology, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VIR with
Follow VIR
Get an email when Vir Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vir Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.